<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00060632</url>
  </required_header>
  <id_info>
    <org_study_id>8669-001</org_study_id>
    <secondary_id>AP23573-02-101</secondary_id>
    <nct_id>NCT00060632</nct_id>
  </id_info>
  <brief_title>Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)</brief_title>
  <official_title>A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Weekly Administration of AP23573, an mTOR Inhibitor, in Patients With Refractory or Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ariad Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      Phase 1 trial to determine the safety, tolerability and maximum tolerated dose (MTD) of&#xD;
      ridaforolimus in patients with refractory or recurrent malignancies, including myeloma and&#xD;
      lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of the study are to determine the safety, tolerability, and MTD of&#xD;
      ridaforolimus when administered once weekly for 4 weeks (4 week cycle). The secondary&#xD;
      objectives of the study are to characterize the pharmacokinetic profile of ridaforolimus, to&#xD;
      evaluate potential pharmacodynamic markers of ridaforolimus, and to obtain preliminary&#xD;
      information on the antineoplastic activity of ridaforolimus.&#xD;
&#xD;
      Protocol Outline: This is a dose-escalation study. Patients receive ridaforolimus over 30&#xD;
      minutes by intravenous infusion once weekly for 8 weeks (two 4-week cycles). If tolerated, a&#xD;
      total of at least 2 cycles will be administered (8-week treatment period). Treatment repeats&#xD;
      every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Cycle 1 (within the first 4 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Adverse Events (AE)</measure>
    <time_frame>Throughout study duration and up to approximately 1 month after the last dosing cycle (Cycle 1 Day 1 to approximately 10 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinuing Due to AEs</measure>
    <time_frame>Throughout study duration (Cycle 1 Day 1 to approximately 9 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Overall Tumor Response</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of Ridaforolimus</measure>
    <time_frame>Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC[0 to Infinity]) of Ridaforolimus</measure>
    <time_frame>Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-Life (t1/2) of Ridaforolimus</measure>
    <time_frame>Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of Ridaforolimus</measure>
    <time_frame>Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of Ridaforolimus</measure>
    <time_frame>Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphorylated 4E Binding Protein 1 (Phospho-4E-BP1) Blood Levels</measure>
    <time_frame>Screening, Cycle 1 Days 1, 2, 3, 6/7, 8; Cycle 2 Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Tumors</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Ridaforolimus 6.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Ridaforolimus 12.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Ridaforolimus 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Ridaforolimus 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Ridaforolimus 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: Ridaforolimus 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ridaforolimus</intervention_name>
    <description>Administered intravenously once weekly for 4 weeks (1 cycle).&#xD;
In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles.</description>
    <arm_group_label>Cohort 1: Ridaforolimus 6.25 mg</arm_group_label>
    <arm_group_label>Cohort 2: Ridaforolimus 12.5 mg</arm_group_label>
    <arm_group_label>Cohort 3: Ridaforolimus 25 mg</arm_group_label>
    <arm_group_label>Cohort 4: Ridaforolimus 50 mg</arm_group_label>
    <arm_group_label>Cohort 5: Ridaforolimus 100 mg</arm_group_label>
    <arm_group_label>Cohort 6: Ridaforolimus 75 mg</arm_group_label>
    <other_name>AP23573</other_name>
    <other_name>MK-8669</other_name>
    <other_name>ridaforolimus was also known as deforolimus until May 2009</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        (Patients must meet each of the following criteria to be eligible for participation in the&#xD;
        study).&#xD;
&#xD;
          -  Male or female patients, ≥ 18 years of age.&#xD;
&#xD;
          -  Patients with a documented measurable or evaluable malignancy, including myeloma or&#xD;
             lymphoma, that is recurrent, advanced, or metastatic.&#xD;
&#xD;
          -  Patients with disease that is currently refractory to, or not amenable to, standard&#xD;
             therapy.&#xD;
&#xD;
          -  Patients with disease that is currently not amenable to surgical intervention.&#xD;
&#xD;
          -  Patients with Karnofsky performance status of ≥ 70% (Eastern Cooperative Oncology&#xD;
             Group [ECOG] performance status of 0 or 1) and an anticipated life expectancy of ≥ 3&#xD;
             months.&#xD;
&#xD;
          -  Patients either not of childbearing potential, or agreeing to use a medically&#xD;
             effective method of contraception.&#xD;
&#xD;
          -  Patients with the ability to understand and give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        (Patients meeting any of the following criteria are ineligible for participation in the&#xD;
        study)&#xD;
&#xD;
          -  Women who are pregnant or lactating.&#xD;
&#xD;
          -  Patients with primary central nervous system (CNS) malignancies. Patients with&#xD;
             leukemia, any form.&#xD;
&#xD;
          -  Patients with certain hematologic abnormalities.&#xD;
&#xD;
          -  Patients with certain serum chemistry abnormalities at baseline.&#xD;
&#xD;
          -  Patients with known or suspected hypersensitivity to either drugs formulated with&#xD;
             polysorbate 80 (Tween 80) or any other excipient contained in the test drug&#xD;
             formulation.&#xD;
&#xD;
          -  Patients with known hypersensitivity to macrolide antibiotics (e.g., clarithromycin,&#xD;
             erythromycin, azithromycin).&#xD;
&#xD;
          -  Patients with significant cardiovascular disease.&#xD;
&#xD;
          -  Patients with active CNS metastases (or leptomeningeal disease) not controlled by&#xD;
             prior surgery or radiotherapy. Note: Patients with treated brain metastases will be&#xD;
             eligible if they are on a stable dose of corticosteroids or are without change in&#xD;
             brain disease status for at least 4 weeks following related therapy (e.g., whole brain&#xD;
             radiation, surgery).&#xD;
&#xD;
          -  Patients with known human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Patients with any active infection.&#xD;
&#xD;
          -  Patients with inadequate recovery from any prior surgical procedure, or patients&#xD;
             having undergone any major surgical procedure within 2 weeks prior to study entry.&#xD;
             Note: Patients having undergone recent placement of a central venous access port will&#xD;
             be considered eligible for enrollment if they have recovered.&#xD;
&#xD;
          -  Patients who have any other life-threatening illness or organ system dysfunction&#xD;
             which, in the opinion of the Investigator, would either compromise the patient's&#xD;
             safety or interfere with evaluation of the safety of the test drug.&#xD;
&#xD;
          -  Patients with a psychiatric disorder or altered mental status that would preclude&#xD;
             understanding of the informed consent process and/or completion of the necessary&#xD;
             studies.&#xD;
&#xD;
          -  Patients with the inability, in the opinion of the Investigator, to comply with the&#xD;
             protocol requirements.&#xD;
&#xD;
        Drugs and Other Treatments to be Excluded (Either during or within 4 weeks prior to study&#xD;
        entry, unless otherwise noted)&#xD;
&#xD;
          -  Chemotherapeutic agents (standard or experimental).&#xD;
&#xD;
          -  Other antineoplastic agents.&#xD;
&#xD;
          -  Immunotherapy (including vaccines) or biological response modifier therapy.&#xD;
&#xD;
          -  Systemic replacement hormonal therapy for life-threatening non-oncology diseases.&#xD;
&#xD;
          -  Herbal preparations or related over-the-counter (OTC) preparations containing herbal&#xD;
             ingredients (e.g., St John's Wort) during or within 2 weeks prior to study entry.&#xD;
&#xD;
          -  Any prior therapy with rapamycin, CCI-779, or any other rapamycin analog.&#xD;
&#xD;
          -  Any other experimental therapy during the course of the study.&#xD;
&#xD;
          -  Radiotherapy for the primary malignancy or metastases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, Loewy JW, Kindler H, Stadler WM, Knowles HL, Bedrosian C, Ratain MJ. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15;15(4):1428-34. doi: 10.1158/1078-0432.CCR-08-2076.</citation>
    <PMID>19228743</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>May 8, 2003</study_first_submitted>
  <study_first_submitted_qc>May 9, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2003</study_first_posted>
  <last_update_submitted>August 26, 2015</last_update_submitted>
  <last_update_submitted_qc>August 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced, refractory or recurrent solid tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

